Exploring the Efficacy of Convalescent Plasma Therapy in COVID-19 Patients: A Clinical Trial Study
Abstract
In December 2019, a group of patients in Wuhan, Hubei province, China,
presented with severe illness and pneumonia of unknown origin. Subsequently, a novel coronavirus
was identified as the cause and named "2019 novel coronavirus" (2019-nCoV), later defined as
"SARS-CoV-2" (Severe Acute Respiratory Syndrome Coronavirus-2), leading to the development of
the disease known as COVID-19. This study aimed to evaluate the effectiveness and safety of convalescent
plasma as a potential therapy for patients with COVID-19.
Patients diagnosed with COVID-19 based on real-time polymerase chain reaction (PCR)
or CT-Scan symptoms were randomly assigned to either the treatment group (n = 29, received convalescent
plasma) or the control group (n = 29). Clinical manifestations and pulmonary involvement
were monitored three times during the study. At the end of the intervention, patients were evaluated
for clinical symptoms, laboratory test results, and length of hospital stay.
Among the 58 patients who completed the study, there were no significant differences in
baseline characteristics between the treatment and control groups upon admission to the hospital.
However, the length of hospital stay was significantly shorter (9.54 days) in the convalescent plasma
group compared to the control group (12.88 days).
The findings from this study indicate that the use of convalescent plasma therapy, in
addition to standard treatment, did not result in reduced mortality or improved clinical outcomes at…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 58 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.